TissueCypher guidance clinically and statistically improved the standard of care by increasing the likelihood of appropriate management decisions for all patients and decreasing the variability in management that results from basing care solely on the diagnoses of dysplasia.
Figure 1 shows the % of appropriate management for all patients was improved by the addition of guidance from TissueCypher to the standard of care (SOC), with the median increasing from 80% to 100%. For progressors there was an increase in the percent receiving EET and a decreased percentage receiving 3-to-5-year surveillance. For non-progressors there was an increased percentage that were managed by 3-to-5-year surveillance.
Figure 2 illustrates the improvement in consistency of management across all 500 simulations. For the standard of care (SOC) 7.1% of patients experienced no deviation in management across all 500 simulations. The addition of guidance from TissueCypher increased this number to 57.1% of patients that saw no deviation across all 500 simulations.